Wuhan Langlai Technology Development

Wuhan Langlai Technology Development, operating as Langlai Pharmaceutical, is a clinical-stage biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on chronic diseases with significant unmet medical needs, particularly in the areas of metabolic, respiratory, and inflammatory disorders. Its lead clinical programs include LR19024, a P2X3 receptor antagonist for chronic cough, and LR19111, a URAT1 inhibitor for the treatment of gout and hyperuricemia. Langlai utilizes a proprietary drug discovery platform to identify and optimize novel chemical entities with improved safety and efficacy profiles. The company maintains a robust pipeline of candidates ranging from pre-clinical research to Phase 2 clinical trials. By leveraging its expertise in medicinal chemistry and pharmacology, Langlai aims to provide high-quality therapeutic solutions for patients globally.